Пневмония, вызываемая «атипичными»возбудителями
Пневмония, вызываемая «атипичными»возбудителями
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Lim WS, Baudouin SV, George RS et al. British Thoracic Society guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64(Suppl III): iii1–55.
2. Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect 2006; 12(Suppl. 3): 12–24.
3. Murray HW, Tuazon C. Atypical pneumonias. Med Clin North Am 1980; 64: 507–27.
4. Martin RE, Bates JH. Atypical pneumonia. Infect Dis Clin North Am 1991; 5: 585–601.
5. Fang MJ, Fine M, Orloff J et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307–16.
6. Mulazimoglu L, Yu VL. Can Legionnaire's disease be diagnosed by clinical criteria? A critical review. Chest 2001; 120: 1049–53.
7. Cunha BA. Pneumonia Essentials. Royal Oak, MI: Physicians Press, 2006.
8. Mandell GL, Bennet JE, Dolin R (eds.). Mandell, Douglas, and Bennet's Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Churchill Livingstone, 2005.
9. Marrie TJ (ed.). Community-Acquired Pneumonia. New York: Kluwer Academic, 2001.
10. Lepow ML, Balassanian N, Emmerich J et al. Interrelationships of viral, mycoplasmal, and bacterial agents in uncomplicated pneumonia. Am Rev Respir Dis 1968; 97: 533–45.
11. Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis 2001; 14: 181–6.
12. Чучалин А.Г., Синопальников А.И., Тартаковский И.С. и др. Практические рекомендации по диагностике и лечению легионеллезной инфекции, вызываемой Legionella pneumophila, серогруппы 1 (пособие для врачей). М., 2009.
13. Тартаковский И.С. Современные подходы к диагностике атипичных пневмоний. Клин микробиол. антимикроб. химиотер. 2000; 1: 60–8.
14. Reese RE, Betts RF, Gumustop B. Handbook of antibiotics. 3rd ed. Philadelphia Lippincott Williams & Wilkins, 2000.
15. File TM, Tan JS, Plouffe JF. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infections. Infect Dis Clin North Am 1998; 12: 569–92.
16. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74: 613–34.
17. Sabria M, Pedro-Botet ML, Gomez J et al. For the Legionniares' disease therapy group. Fluoroquinolones versus macrolides in the treatment of Legionnaire's disease. Chest 2005; 128: 1401–5.
18. Mykietiuk A, Carratala J, Ferna.ndez-Sabe N et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40: 794–9.
19. Blazquez-Garrido RM, Espinosa Parra FJ, Alemany et al. Antimicrobial chemotherapy for Legionnaire's disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40: 800–6.
20. Meyer RD, Edelstein PH, Kirby BD et al. Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med. 1980; 93: 240–3.
2. Cunha BA. The atypical pneumonias: clinical diagnosis and importance. Clin Microbiol Infect 2006; 12(Suppl. 3): 12–24.
3. Murray HW, Tuazon C. Atypical pneumonias. Med Clin North Am 1980; 64: 507–27.
4. Martin RE, Bates JH. Atypical pneumonia. Infect Dis Clin North Am 1991; 5: 585–601.
5. Fang MJ, Fine M, Orloff J et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine 1990; 69: 307–16.
6. Mulazimoglu L, Yu VL. Can Legionnaire's disease be diagnosed by clinical criteria? A critical review. Chest 2001; 120: 1049–53.
7. Cunha BA. Pneumonia Essentials. Royal Oak, MI: Physicians Press, 2006.
8. Mandell GL, Bennet JE, Dolin R (eds.). Mandell, Douglas, and Bennet's Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Churchill Livingstone, 2005.
9. Marrie TJ (ed.). Community-Acquired Pneumonia. New York: Kluwer Academic, 2001.
10. Lepow ML, Balassanian N, Emmerich J et al. Interrelationships of viral, mycoplasmal, and bacterial agents in uncomplicated pneumonia. Am Rev Respir Dis 1968; 97: 533–45.
11. Hammerschlag MR. Mycoplasma pneumoniae infections. Curr Opin Infect Dis 2001; 14: 181–6.
12. Чучалин А.Г., Синопальников А.И., Тартаковский И.С. и др. Практические рекомендации по диагностике и лечению легионеллезной инфекции, вызываемой Legionella pneumophila, серогруппы 1 (пособие для врачей). М., 2009.
13. Тартаковский И.С. Современные подходы к диагностике атипичных пневмоний. Клин микробиол. антимикроб. химиотер. 2000; 1: 60–8.
14. Reese RE, Betts RF, Gumustop B. Handbook of antibiotics. 3rd ed. Philadelphia Lippincott Williams & Wilkins, 2000.
15. File TM, Tan JS, Plouffe JF. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infections. Infect Dis Clin North Am 1998; 12: 569–92.
16. Alvarez-Elcoro S, Enzler MJ. The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clin Proc 1999; 74: 613–34.
17. Sabria M, Pedro-Botet ML, Gomez J et al. For the Legionniares' disease therapy group. Fluoroquinolones versus macrolides in the treatment of Legionnaire's disease. Chest 2005; 128: 1401–5.
18. Mykietiuk A, Carratala J, Ferna.ndez-Sabe N et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005; 40: 794–9.
19. Blazquez-Garrido RM, Espinosa Parra FJ, Alemany et al. Antimicrobial chemotherapy for Legionnaire's disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40: 800–6.
20. Meyer RD, Edelstein PH, Kirby BD et al. Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med. 1980; 93: 240–3.
Авторы
.И.Синопальников
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.